Most health insurance plans will cover the cost of genetic testing when recommended by a physician. However, all coverage and reimbursement is subject to Medicare, Medicaid, and third-party payer benefit plans. Therefore, ASCO strongly encourages you to verify with the patient’s insurer to understand what type of services will be covered.
Common CPT Billing Codes for Genetic Risk Assessment
CPT* codes and descriptions are subject to change on an annual basis. Be sure to check the AMA CPT Professional Edition on an annual basis for any updates or edits to these codes.
- 99401 Preventive medicine counseling/risk factor reduction, 15 minutes
- 99402 Preventive medicine counseling/risk factor reduction, 30 minutes
- 99403 Preventive medicine counseling/risk factor reduction, 45 minutes
- 99404 Preventive medicine counseling/risk factor reduction, 60 minutes
- 81201 APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated (FAP) gene analysis; full gene sequence
- 81202 APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated (FAP) gene analysis; known familial variants,
- 81203 APC (adenomatous polyposis coli) (e.g., familial adenomatosis polyposis [FAP], attenuated (FAP) gene analysis; duplication/deletion variants
- 81211 BRCA1, BRCA2 (breast cancer 1 and 2) (eg, hereditary breast and ovarian cancer gene analysis; full sequence analysis and common duplication/deletion variants in BRCA1 (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)
- 81212 185delAG, 5385insC, 6174deIT variants
- 81213 Uncommon duplication/deletion variants
- 81214 BRCA1 (breast cancer 1) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and common duplication/deletion variants (ie, exon 13 del 3.835kb, exon 13 dup 6kb, exon 14-20 del 26kb, exon 22 del 510bp, exon 8-9 del 7.1kb)
- 81215 Known familial variant
- 81216 BRCA 2 (breast cancer 2) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis
- 81217 Known familial variant
- 81292 MLH1 (mutL homolog1, colon cancer, nonpolyposis type 2)(e.g. hereditary non-polyposis colorectal cancer, Lynch Syndrome) gene analysis; full sequence
- 81288 Promoter methylation analysis
- 81293 Known familial variants
- 81294 Duplication/deletion variants
- 81295 MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1)(e.g. hereditary non-polyposis colorectal cancer, Lynch Syndrome) gene analysis; full sequence analysis
- 81296 Known familial variants
- 81297 Duplication/deletion variants
- 81298 MSH6 (mutS homolog 6 [E.coli]) (e.g. hereditary non-polyposis colorectal cancer, Lynch Syndrome) gene analysis; full sequence
- 81299 Known familial variants
- 81300 Duplication/deletion variants
- 81301 Microsatellite instability analysis (.e. hereditary non-polyposis colorectal cancer, Lynch Syndrome) of markers for mismatch repair deficiency (e.g. BAT25, BAT26) includes comparison of neoplastic and normal tissue, if performed
- 81317 PMS2 (postmeiotic segregation increased 2 [S. cerevisiae]) (e.g. hereditary non-polyposis colorectal cancer, Lynch Syndrome) gene anaylysis; full sequence analysis
- 81318 Known familial variants
- 81319 Duplication/deletion variants
- 81312 PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; full sequence analysis
- 81322 PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; known familial variant
- 81323 PTEN (phosphatase and tensin homolog) (e.g., Cowden syndrome, PTEN hamartoma tumor syndrome) gene analysis; duplication/deletion variant
*CPT © copyright 2015 American Medical Association. All rights Reserved. CPT is a registered trademark of the American Medical Association.
Genetic Testing Coverage Policies of Major Carriers
Genetic Testing Insurance Coverage Trends: A review of publicly available policies from the largest US payers (2013)
Blue Cross Blue Shield (Coverage varies by state)
- New York (Excellus)
- North Carolina, Testing for Breast and Ovarian Cancer
- Rhode Island
- Washington (Premera)
Cigna: Genetic Testing and Counseling Program
Medicare is prevented from covering preventive services unless explicitly authorized by Congress. Tests performed in the absence of signs, symptoms, complaints, or personal histories of disease or injury are not covered unless explicitly authorized by statute; a family history of disease does not meet the personal history criterion.
Medicare coverage for genetic counseling is also limited by the program’s screening exclusion. Therefore, Medicare does not currently provide coverage for genetic testing in individuals without a personal history of cancer. However, Medicare will cover genetic testing for BRCA1 and BRCA2 under the following conditions:
- An individual with a personal history of breast cancer and one or more of the following:
- Diagnosis before the age of 45 with or without a family history
- Diagnosis before the age of 50 or two breast primaries, with at least one close blood relative with breast cancer diagnosed before 50, or at least one close blood relative with ovarian cancer/fallopian tube/primary peritoneal cancer
- Two breast primaries when first breast cancer diagnosis occurred prior to age 50
- Diagnosis at any age, with at least two close blood relatives with breast and/or epithelial ovarian/fallopian tube/primary peritoneal cancer
- A close male blood relative with breast cancer
- A personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer
- Of an ethnicity associated with higher mutation frequency (e.g., Ashkenazi Jewish); no additional family history required
- A close relative with a known BRCA1 or BRCA2 gene mutation
2. An individual with a personal history of epithelial ovarian/fallopian tube/primary peritoneal cancer
3. A male with a personal history of male breast cancer
Medicare also provides coverage for Lynch syndrome (hereditary nonpolyposis colorectal cancer (HNPCC)) for those who meet any of the following criteria:
- Individuals with a first-degree relative with known mutation
- Individuals meeting either the revised Bethesda guidelines or Amsterdam Criteria (see table below)
- Individuals diagnosed with endometrial cancer under age 50. (Endometrial cancer for those under 50 years is not included in the revised Bethesda guidelines, however, per the NCCN, recent evidence suggests these individuals should be evaluated for Lynch syndrome)
Amsterdam II criteria
Revised Bethesda Guidelines
At least three relatives must have a cancer associated with HNPCC (colorectal, cancer of uterus, small bowel, ureter and renal pelvis); and ALL of the following criteria should be present:
Individual must meet ONE of the following criteria:
* MSH6 sequence analysis is considered medically necessary for persons meeting the above criteria for genetic testing for HNPCC, and who do not have mutations in either the MLH1 or MSH2 genes; or single site MSH6 testing for testing family members of persons with HNPCC with an identified MSH6 gene mutation. PMS2 mutation testing is only necessary if no mutation is found in the other genes.
**Microsatellite instability (MSI) testing or immunohistochemical (IHC) analysis of the tumor is considered medically necessary as a preliminary testing strategy in individuals with colorectal cancer who meet the revised Bethesda guidelines in an effort to identify those individuals who should proceed with HNPCC mutation analysis.
***Lynch syndrome tumors/cancer include colorectal, endometrial, gastric, ovarian, pancreas, ureter and renal pelvis, biliary tract, brain (usually glioblastoma as seen in Turcot Syndrome), and small intestinal cancers, as well as sebaceous gland adenomas and keratoacanthomas in Muir-Torre syndrome.
Several state Medicaid programs offer coverage for BRCA testing, however this coverage varies by state. Further, the Essential Health Benefits Package of the Affordable Care Act (ACA) includes a provision for coverage of genetic counseling related to hereditary breast cancer because it has a USPSTF B rating, however the law is silent about covering the cost of the genetic testing for a BRCA mutation. It is important to note that this provision applies only to those Medicaid patients who are newly eligible under the ACA Medicaid expansion and does not apply to current Medicaid beneficiaries. The ACA does provide an incentive (1% increase in Federal Medical Assistance Percentage) for states that provide coverage for their current Medicaid recipients. ASCO recommends consulting your state Medicaid guidelines to understand what genetic testing and counseling services may be covered for your patients. To find out what your state Medicaid program may cover, visit the State Medicaid & CHIP Profiles page.
Genetics Provisions in the Affordable Care Act
With the passage of the Affordable Care Act (ACA), beginning in 2014, health insurance plans cannot refuse coverage to an individual nor charge more for coverage because of an individual’s pre-existing health condition. Further, once an individual has insurance coverage, the coverage cannot refuse to cover treatment due to a pre-existing condition; this is true even if a patient has been turned down or refused coverage in the past.
One exception: Grandfathered individual health insurance plans. The only exception is for grandfathered individual health insurance plans--the kind purchased by an individual and not provided through an employer. These policies do not have to cover preexisting conditions. However, an individual can now switch to a Marketplace plan during open enrollment and immediately get coverage for the preexisting conditions.
The ACA established a set of “Essential Health Benefits,” or core services that must be offered by individual and group insurers with no co-pay. Specifically for women who are at an increased risk, plans are required to cover, without copay, counseling and genetic testing for BRCA mutations. However, coverage of genetic counseling and testing for other cancer syndromes is not required under the ACA, leaving this provision up to individual health plans to determine if and how they will cover these services. Further, the law removes the ability of insurance plans to have lifetime coverage limits.